These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


173 related items for PubMed ID: 3027850

  • 1. Early experience with itraconazole in vitro and in patients: pharmacokinetic studies and clinical results.
    Dupont B, Drouhet E.
    Rev Infect Dis; 1987; 9 Suppl 1():S71-6. PubMed ID: 3027850
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses.
    Grant SM, Clissold SP.
    Drugs; 1989 Mar; 37(3):310-44. PubMed ID: 2540949
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Treatment of pulmonary aspergilloma with itraconazole.
    Campbell JH, Winter JH, Richardson MD, Shankland GS, Banham SW.
    Thorax; 1991 Nov; 46(11):839-41. PubMed ID: 1663275
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [In-vitro and in-vivo activity of itraconazole].
    Van Cutsem J.
    Med Klin (Munich); 1991 Dec; 86 Suppl 1():5-8. PubMed ID: 1663204
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Comparison of azoles against aspergilli in vitro and in an experimental model of pulmonary aspergillosis.
    Schmitt HJ, Edwards F, Andrade J, Niki Y, Armstrong D.
    Chemotherapy; 1992 Dec; 38(2):118-26. PubMed ID: 1317280
    [Abstract] [Full Text] [Related]

  • 12. Complete eradication of Aspergillus fumigatus from the lung in an immunocompromised patient by oral itraconazole.
    Moore L, Ellis DH, Suppiah R, Byard RW, Toogood IR.
    J Paediatr Child Health; 1993 Apr; 29(2):141-3. PubMed ID: 8387801
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. European experience with itraconazole in systemic mycoses.
    Viviani MA, Tortorano AM, Pagano A, Vigevani GM, Gubertini G, Cristina S, Assaisso ML, Suter F, Farina C, Minetti B.
    J Am Acad Dermatol; 1990 Sep; 23(3 Pt 2):587-93. PubMed ID: 2170478
    [Abstract] [Full Text] [Related]

  • 15. A comparison of the efficacy of itraconazole, amphotericin B and 5-fluorocytosine in the treatment of Aspergillus fumigatus endocarditis in the rabbit.
    Longman LP, Martin MV.
    J Antimicrob Chemother; 1987 Nov; 20(5):719-24. PubMed ID: 2828301
    [Abstract] [Full Text] [Related]

  • 16. Tissue distribution and antifungal effect of liposomal itraconazole in experimental cryptococcosis and pulmonary aspergillosis.
    Le Conte P, Joly V, Saint-Julien L, Gillardin JM, Carbon C, Yeni P.
    Am Rev Respir Dis; 1992 Feb; 145(2 Pt 1):424-9. PubMed ID: 1310577
    [Abstract] [Full Text] [Related]

  • 17. Itraconazole, a new triazole that is orally active in aspergillosis.
    Van Cutsem J, Van Gerven F, Van de Ven MA, Borgers M, Janssen PA.
    Antimicrob Agents Chemother; 1984 Oct; 26(4):527-34. PubMed ID: 6097167
    [Abstract] [Full Text] [Related]

  • 18. [The therapeutic effects of itraconazole, a new triazole antifungal agent, for experimental fungal infections].
    Uchida K, Yamaguchi H, Shibuya K.
    Jpn J Antibiot; 1991 May; 44(5):588-99. PubMed ID: 1652657
    [Abstract] [Full Text] [Related]

  • 19. [Mycoses as opportunistic infections in AIDS patients].
    Viviani MA.
    Med Klin (Munich); 1991 Dec; 86 Suppl 1():19-22. PubMed ID: 1663202
    [Abstract] [Full Text] [Related]

  • 20. Itraconazole therapy in aspergillosis: study in 49 patients.
    Dupont B.
    J Am Acad Dermatol; 1990 Sep; 23(3 Pt 2):607-14. PubMed ID: 2170481
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 9.